ALK-Abelló A/S narrowed the revenue guidance for the full year 2023. For the period, the company expected revenue to grow by 8% to 10% organically in local currencies (previously: 7% to 11%), which is equivalent to 9% to 11% growth, disregarding the one-year temporary mandatory rebate increase for prescription drugs in Germany.